ArticleAesthetic plastic surgery2025
Concentrated Micronized Fat Ameliorates Skin Fibrosis in Bleomycin-Induced Murine Model and Enhances Fat Graft Survival.
Article in Aesthetic plastic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundScleroderma is characterized by fibrosis of the skin and internal organs, vascular abnormalities, and immune dysregulation. Fat grafting has emerged as a promising therapeutic approach for improving soft tissue deficits and alleviating fibrosis in scleroderma patients. However, low fat graft survival and unresolved fibrosis in fibrotic tissues limit its efficacy. This study aims to evaluate the efficacy of Concentrated Micronized Fat (CMF), a mechanically processed fat product enriched with stromal vascular fraction (SVF) cells and intact adipocytes, in mitigating bleomycin-induced skin fibrosis and enhancing fat graft survival.
methodCMF was prepared using a mechanical micronization and filtration-adsorption method to enrich stromal vascular fraction cells while retaining intact adipocytes. In vitro experiments assessed the effects of CMF on fibroblast proliferation and migration. A murine model of bleomycin (BLM)-induced skin fibrosis was established, and the therapeutic effects of CMF and Coleman fat were compared through in vivo transplantation.
resultIn vitro experiments showed that CMF significantly inhibited fibroblast proliferation and migration. In vivo, CMF transplantation effectively mitigated bleomycin-induced dermal thickening and collagen deposition while promoting adipocyte survival.
conclusionCMF effectively alleviates skin fibrosis. It improves fat graft retention under fibrotic conditions. These results suggest that CMF is a promising therapeutic approach for treating scleroderma-related fibrosis. NO LEVEL ASSIGNED: This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
41060404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.